Annual CFF
$86.51 M
-$533.73 M-86.05%
December 31, 2023
Summary
- As of February 7, 2025, SMMT annual cash flow from financing activities is $86.51 million, with the most recent change of -$533.73 million (-86.05%) on December 31, 2023.
- During the last 3 years, SMMT annual CFF has risen by +$35.96 million (+71.14%).
- SMMT annual CFF is now -86.05% below its all-time high of $620.24 million, reached on December 31, 2022.
Performance
SMMT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$204.14 M
+$3.93 M+1.96%
September 30, 2024
Summary
- As of February 7, 2025, SMMT quarterly cash flow from financing activities is $204.14 million, with the most recent change of +$3.93 million (+1.96%) on September 30, 2024.
- Over the past year, SMMT quarterly CFF has increased by +$3.93 million (+1.96%).
- SMMT quarterly CFF is now -60.75% below its all-time high of $520.06 million, reached on December 31, 2022.
Performance
SMMT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$411.09 M
+$203.91 M+98.42%
September 30, 2024
Summary
- As of February 7, 2025, SMMT TTM cash flow from financing activities is $411.09 million, with the most recent change of +$203.91 million (+98.42%) on September 30, 2024.
- Over the past year, SMMT TTM CFF has increased by +$203.91 million (+98.42%).
- SMMT TTM CFF is now -39.11% below its all-time high of $675.17 million, reached on March 31, 2023.
Performance
SMMT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SMMT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -86.0% | +2.0% | +98.4% |
| 3 y3 years | +71.1% | -60.8% | -33.7% |
| 5 y5 years | +94.4% | +10000.0% | +1459.0% |
SMMT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.0% | +11.0% | -60.8% | >+9999.0% | -39.1% | +5869.9% |
| 5 y | 5-year | -86.0% | +74.8% | -60.8% | >+9999.0% | -39.1% | >+9999.0% |
| alltime | all time | -86.0% | >+9999.0% | -60.8% | +7869.1% | -39.1% | >+9999.0% |
Summit Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $204.14 M(+2.0%) | $411.09 M(+98.4%) |
| Jun 2024 | - | $200.21 M(>+9900.0%) | $207.18 M(+2908.7%) |
| Mar 2024 | - | $485.00 K(-92.2%) | $6.89 M(-92.0%) |
| Dec 2023 | $86.51 M(-86.1%) | $6.25 M(+2630.1%) | $86.51 M(-85.6%) |
| Sep 2023 | - | $229.00 K(-386.3%) | $600.32 M(-11.1%) |
| Jun 2023 | - | -$80.00 K(-100.1%) | $675.09 M(-0.0%) |
| Mar 2023 | - | $80.11 M(-84.6%) | $675.17 M(+8.9%) |
| Dec 2022 | $620.24 M(+696.0%) | $520.06 M(+593.4%) | $620.24 M(+511.4%) |
| Sep 2022 | - | $75.00 M(>+9900.0%) | $101.44 M(+274.0%) |
| Jun 2022 | - | $0.00(-100.0%) | $27.12 M(-42.5%) |
| Mar 2022 | - | $25.19 M(+1897.4%) | $47.21 M(-39.4%) |
| Dec 2021 | $77.92 M(+54.1%) | $1.26 M(+86.5%) | $77.92 M(-38.7%) |
| Sep 2021 | - | $676.00 K(-96.6%) | $127.20 M(+0.5%) |
| Jun 2021 | - | $20.08 M(-64.1%) | $126.53 M(+18.9%) |
| Mar 2021 | - | $55.90 M(+10.6%) | $106.44 M(+110.6%) |
| Dec 2020 | $50.55 M(+2.1%) | - | - |
| Dec 2020 | - | $50.55 M(>+9900.0%) | $50.55 M(>+9900.0%) |
| Sep 2020 | - | $0.00(0.0%) | $3000.00(-102.4%) |
| Jun 2020 | - | $0.00(-100.0%) | -$125.00 K(-45.1%) |
| Mar 2020 | - | $3000.00(-102.3%) | -$227.70 K(-100.9%) |
| Dec 2019 | $49.51 M(+11.2%) | - | - |
| Oct 2019 | - | -$128.00 K(+24.6%) | $26.37 M(+2.2%) |
| Jul 2019 | - | -$102.70 K(-9.8%) | $25.80 M(+3.6%) |
| Apr 2019 | - | -$113.80 K(-100.4%) | $24.90 M(-44.0%) |
| Jan 2019 | $44.51 M(+128.6%) | - | - |
| Jan 2019 | - | $26.71 M(-3909.8%) | $44.51 M(+135.5%) |
| Oct 2018 | - | -$701.20 K(-29.6%) | $18.90 M(-50.2%) |
| Jul 2018 | - | -$995.60 K(-105.1%) | $37.92 M(-2.6%) |
| Apr 2018 | - | $19.49 M | $38.95 M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2018 | $19.47 M(+3672.0%) | - | - |
| Jan 2018 | - | $1.10 M(-94.0%) | $19.47 M(+5.8%) |
| Oct 2017 | - | $18.33 M(>+9900.0%) | $18.40 M(+4676.9%) |
| Jul 2017 | - | $27.90 K(+66.1%) | $385.20 K(+2.3%) |
| Apr 2017 | - | $16.80 K(-44.4%) | $376.70 K(-27.0%) |
| Jan 2017 | $516.20 K(-98.4%) | - | - |
| Jan 2017 | - | $30.20 K(-90.3%) | $516.30 K(-124.1%) |
| Oct 2016 | - | $310.30 K(+1499.5%) | -$2.14 M(-24.5%) |
| Jul 2016 | - | $19.40 K(-87.6%) | -$2.83 M(+24.0%) |
| Apr 2016 | - | $156.40 K(-106.0%) | -$2.29 M(-107.3%) |
| Jan 2016 | $31.53 M(+3.4%) | - | - |
| Jan 2016 | - | -$2.63 M(+585.9%) | $31.53 M(-0.8%) |
| Oct 2015 | - | -$383.10 K(-167.5%) | $31.77 M(+5.9%) |
| Jul 2015 | - | $567.40 K(-98.3%) | $30.01 M(+1.5%) |
| Apr 2015 | - | $33.97 M(-1524.6%) | $29.58 M(-2.9%) |
| Jan 2015 | $30.48 M(+314.6%) | - | - |
| Jan 2015 | - | -$2.38 M(+11.5%) | $30.48 M(-7.3%) |
| Oct 2014 | - | -$2.14 M(-1653.3%) | $32.86 M(-6.1%) |
| Jul 2014 | - | $137.70 K(-99.6%) | $35.00 M(+0.4%) |
| Apr 2014 | - | $34.86 M | $34.86 M |
| Jan 2014 | $7.35 M(+2.2%) | - | - |
| Jan 2013 | $7.19 M(+237.6%) | - | - |
| Jan 2012 | $2.13 M(+8322.5%) | - | - |
| Jan 2011 | $25.30 K(-99.7%) | - | - |
| Jan 2010 | $8.14 M(+53.2%) | - | - |
| Jan 2009 | $5.31 M(+298.2%) | - | - |
| Jan 2008 | $1.33 M(-93.1%) | - | - |
| Jan 2007 | $19.38 M(+1333.9%) | - | - |
| Jan 2006 | $1.35 M(-94.9%) | - | - |
| Jan 2005 | $26.47 M | - | - |
FAQ
- What is Summit Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Summit Therapeutics?
- What is Summit Therapeutics annual CFF year-on-year change?
- What is Summit Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Summit Therapeutics?
- What is Summit Therapeutics quarterly CFF year-on-year change?
- What is Summit Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Summit Therapeutics?
- What is Summit Therapeutics TTM CFF year-on-year change?
What is Summit Therapeutics annual cash flow from financing activities?
The current annual CFF of SMMT is $86.51 M
What is the all time high annual CFF for Summit Therapeutics?
Summit Therapeutics all-time high annual cash flow from financing activities is $620.24 M
What is Summit Therapeutics annual CFF year-on-year change?
Over the past year, SMMT annual cash flow from financing activities has changed by -$533.73 M (-86.05%)
What is Summit Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SMMT is $204.14 M
What is the all time high quarterly CFF for Summit Therapeutics?
Summit Therapeutics all-time high quarterly cash flow from financing activities is $520.06 M
What is Summit Therapeutics quarterly CFF year-on-year change?
Over the past year, SMMT quarterly cash flow from financing activities has changed by +$3.93 M (+1.96%)
What is Summit Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SMMT is $411.09 M
What is the all time high TTM CFF for Summit Therapeutics?
Summit Therapeutics all-time high TTM cash flow from financing activities is $675.17 M
What is Summit Therapeutics TTM CFF year-on-year change?
Over the past year, SMMT TTM cash flow from financing activities has changed by +$203.91 M (+98.42%)